Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) and Immunic (NASDAQ:IMUX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.
Risk & Volatility
Zealand Pharma A/S has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Zealand Pharma A/S and Immunic, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zealand Pharma A/S | 0 | 7 | 0 | 3 | 2.60 |
| Immunic | 1 | 1 | 6 | 3 | 3.00 |
Profitability
This table compares Zealand Pharma A/S and Immunic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zealand Pharma A/S | 68.82% | 41.80% | 38.49% |
| Immunic | N/A | -220.75% | -132.04% |
Insider & Institutional Ownership
51.8% of Immunic shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Zealand Pharma A/S and Immunic”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zealand Pharma A/S | $1.40 billion | 2.24 | $977.29 million | $13.48 | 3.25 |
| Immunic | N/A | N/A | -$97.17 million | ($5.58) | -2.65 |
Zealand Pharma A/S has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Zealand Pharma A/S beats Immunic on 7 of the 13 factors compared between the two stocks.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
About Immunic
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
